What is the 13F Pro Quality Score for ALMS?

13F Pro ranks ALUMIS INC. (ALMS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALMS's current score at https://13fpro.ai/research/ALMS (free sign-up required for the full ranking).

Which hedge funds own the most ALMS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALMS include BlackRock,, Deep Track Capital,, Samsara BioCapital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ALMS as soon as new 13F filings post.

Where does 13F Pro source ALMS data?

All ALUMIS INC. fundamentals and ownership data come directly from SEC EDGAR. ALUMIS INC. files with the SEC under CIK 1847367. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALMS in?

ALUMIS INC. (ALMS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALMS research updated on 13F Pro?

ALMS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ALUMIS INC.(ALMS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1847367 ALMS stock profile & AI dashboard →

13F Pro Quality Score

9.2/100

Rank #2,817 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.5/100

Profitability

2.3/100

Balance Sheet

2.4/100

Earnings Quality

30.0/100

Free Cash Flow

1.7/100

Institutional Flow

99.1/100

Revenue Scale

5.9/100

Dilution Risk

2.0/100

ALMS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ALUMIS INC. (ALMS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALMS at 9.2/100 on a 32-signal composite quality model, placing it at rank #2,817 of 2,879 stocks — the bottom half of the AI-ranked universe. ALMS scores in the top quartile across institutional flow (99.1). Areas of concern include free cash flow (1.7) and profitability (2.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ALUMIS INC. reports quarterly revenue of $1.7M, net income of $-93.1M, free cash flow of $-87.2M. Top institutional holders of ALMS by reported 13-F value include BlackRock,, Deep Track Capital,, Samsara BioCapital,, based on the most recent SEC filings. ALMS trades on the Nasdaq exchange and files with the SEC under CIK 1847367. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALUMIS INC. directly from SEC EDGAR. ALUMIS INC.'s 13F Pro composite quality score has ranged between 6 and 19 since 2026, currently 9.2 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.7M

Net Income

Q1 2026

$-93.1M

Free Cash Flow

Q1 2026

$-87.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$24.1MFY 2025

FY22 —FY23 —FY25 $24.1M

Net Income

-57.0% YoY

$-243.3MFY 2025

FY22 —FY23 $-155.0MFY25 $-243.3M

Operating Income

-186.9% YoY

$-453.8MFY 2025

FY22 —FY23 $-158.2MFY25 $-453.8M

EPS (Diluted)

+96.0% YoY

$-2.86FY 2025

FY22 —FY23 $-72.08FY25 $-2.86

Total Assets

+359.7% YoY

$411.9MFY 2025

FY22 —FY23 $89.6MFY25 $411.9M

Op. Cash Flow

-184.3% YoY

$-369.5MFY 2025

FY22 —FY23 $-130.0MFY25 $-369.5M

Metric	FY 2025	FY 2023	FY 2022
Revenue	$24.1M	—	—
Net Income	$-243.3M -57.0%	$-155.0M	—
Operating Income	$-453.8M -186.9%	$-158.2M	—
EPS (Diluted)	$-2.86 +96.0%	$-72.08	—
Total Assets	$411.9M +359.7%	$89.6M	—
Operating Cash Flow	$-369.5M -184.3%	$-130.0M	—

AI Insight: ALMS Financial Trends

ALMS remains pre-commercial with minimal revenue ($2M in latest quarter) and persistent operating losses ($98M in Q1 2026), while equity volatility signals ongoing capital raises.

• Revenue collapsed from $17M (Q1 2025) to $2M (Q1 2026), a 88% decline; company appears in early/failed commercialization phase.

• Operating losses have widened and stabilized around $98–115M per quarter (Q3 2025–Q1 2026), showing no margin improvement trajectory.

• Equity surged to $567M in Q1 2026 from $301M in Q4 2025, consistent with dilutive financing to fund ongoing losses.

⚠ Operating cash burn remains severe at $87M in Q1 2026; company will require additional capital within quarters if trend persists.

⚠ Revenue trajectory suggests product failure or market rejection; no path to profitability visible in current data.

AI Insight: ALMS Ratio Trends

ALMS swung from 48.9% ROE in Q2 2025 to persistent losses across profitability metrics; TTM ROIC deteriorated to -79.5%.

• ROE collapsed from 48.9% in Q2 2025 to -123.4% in Q4 2025, then partially recovered to -65.6% in Q1 2026.

• ROA declined from 38.8% in Q2 2025 to -90.8% in Q3 2025, remaining deeply negative at -55.4% in Q1 2026.

• TTM ROIC stands at -79.5% as of Q1 2026, indicating sustained negative returns on invested capital.

⚠ Q2 2025 profitability spike (48.9% ROE) was followed by severe deterioration; assess whether Q2 reflected one-off gains or sustainable operations.

⚠ Volatility in ROE/ROA quarter-to-quarter suggests inconsistent or lumpy earnings; operational stability remains questionable.

Get alerted when ALMS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ALUMIS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALMS

BlackRock, Inc.
$158.0M7,170,868 sh
Deep Track Capital, LP
$149.2M6,772,595 sh
Samsara BioCapital, LLC
$139.8M6,345,219 sh
Foresite Capital Management V, LLC
$129.9M5,896,995 sh
venBio Partners LLC
$99.8M4,528,408 sh
Foresite Capital Management VI LLC
$93.6M4,247,670 sh
VANGUARD CAPITAL MANAGEMENT LLC
$88.8M4,032,266 sh
Cormorant Asset Management, LP
$87.0M3,949,241 sh
Nextech Invest, Ltd.
$78.0M3,540,998 sh
Saturn V Capital Management LP
$70.5M3,202,075 sh

Fund	Value	Shares
BlackRock, Inc.	$158.0M	7,170,868
Deep Track Capital, LP	$149.2M	6,772,595
Samsara BioCapital, LLC	$139.8M	6,345,219
Foresite Capital Management V, LLC	$129.9M	5,896,995
venBio Partners LLC	$99.8M	4,528,408
Foresite Capital Management VI LLC	$93.6M	4,247,670
VANGUARD CAPITAL MANAGEMENT LLC	$88.8M	4,032,266
Cormorant Asset Management, LP	$87.0M	3,949,241
Nextech Invest, Ltd.	$78.0M	3,540,998
Saturn V Capital Management LP	$70.5M	3,202,075

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALMS on your watchlist

Track score changes the day ALUMIS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALMS a good stock to buy?

13F Pro's AI-powered analysis of ALUMIS INC. (ALMS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALMS are available on the ALMS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALMS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALMS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALUMIS INC.'s investment landscape.